DOI 10.64898/2026.06.22.26356283
SWI and T2*-GRE Microhemorrhage Counts in Anti-Amyloid Therapy Eligibility: A Real-World-Calibrated Simulation Study.
Аннотация
INTRODUCTION
Anti-amyloid therapy eligibility excludes patients with five or more cerebral microhemorrhages (CMHs), but current guidance allows either T2*-GRE or the more sensitive SWI. This may create sequence-dependent differences in eligibility classification.
METHODS
We fitted a Bayesian right-censored zero-inflated Poisson model to single-center real-world SWI-based CMH counts from 130 memory clinic patients. We then simulated T2*-GRE counts under a directional binomial detection model across a range of relative detection probabilities and estimated two metrics: P(T2* <5 | SWI ≥5) and P(SWI ≥5 | T2* <5).
RESULTS
The model estimated a zero-inflation probability of 0.57 and a Poisson mean of 2.29 in the susceptible subpopulation. In the illustrative 60% relative-detection scenario, the model estimated nearly 80% under-detection among SWI-ineligible patients, whereas approximately 5% of T2*-GRE-eligible patients would have been classified as ineligible by SWI.
DISCUSSION: A uniform numeric CMH threshold may not be operationally equivalent across SWI and T2*-GRE. Standardized paired-sequence outcome studies are needed to determine whether SWI-defined and T2*-GRE-defined thresholds carry equivalent ARIA risk.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.